1
|
Wu H, Cheng X, Huang F, Shao G, Meng Y, Wang L, Wang T, Jia X, Yang T, Wang X, Fu C. Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo. DRUG DESIGN DEVELOPMENT AND THERAPY 2020; 14:2413-2422. [PMID: 32606608 PMCID: PMC7308242 DOI: 10.2147/dddt.s244648] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Accepted: 05/07/2020] [Indexed: 12/24/2022]
Abstract
Purpose Acute myeloid leukemia (AML) is a complex malignancy characterized by the clonal expansion of immature myeloid precursors. The standard treatment for newly diagnosed AML is chemotherapy consisting of cytosine arabinoside (Ara-C) and anthracyclines with disappointing clinical outcomes and severe adverse effects, such as symptomatic bradycardia, neurotoxicity. Thus, it is promising to treat AML through combination drug therapy to reduce the adverse effects of chemotherapeutics. In our recent published PNAS paper, we reported that NK-1R antagonists, both Aprepitant and SR140333, induce apoptosis of myeloid leukemia cells by inducing oxidative stress through mitochondrial calcium overload. We, therefore, tested the hypothesis of the combination Ara-C with NK-1R antagonist could enhance the efficacy of Ara-C. Methods MTT assay was employed to detect the cell proliferation. Flow cytometry was applied to detect the cell cycle and necrosis. PI uptake and LDH release assay were used to detect the disintegration of the plasma membrane. Xenograft model was constructed to explore the effect of combination Ara-C with Aprepitant in vivo. Results Our results showed that Aprepitant sensitizes HL60 cells to the cytotoxic effects of Ara-C more than 5-fold by enhancing G0/G1 cell cycle arrest and necrosis in vitro. Furthermore, Nec-1, a specific inhibitor of necroptosis, could recover the cell proliferative viability significantly. Attractively, once every 2-days regimen of Ara-C (5 mg/kg) and Aprepitant (10 mg/kg) via in situ injection dramatically reduced the tumor volume from 2175.0 ± 341.9 mm3 in the vehicle group to 828.4 ± 232.4 mm3 in the combination group without obvious toxicity in human myeloid leukemia xenograft mice. Conclusion Taken together, reduced dose of Ara-C combination with moderate Aprepitant provides more effective therapeutical methods for AML treatment in vitro and in vivo with the elimination of the toxicity of Ara-C, which may pay new avenue for the usage of the routine chemotherapy drug Ara-C with low dose to enhance efficacy and reduce toxicity in clinical practice.
Collapse
Affiliation(s)
- Hongzhang Wu
- Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
| | - Xurui Cheng
- Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
| | - Feiyan Huang
- Clinical Laboratory, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, People's Republic of China
| | - Gang Shao
- Department of Oncology, The 903rd Hospital of PLA, Hangzhou 310013, People's Republic of China
| | - Yueming Meng
- Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
| | - Lingfei Wang
- Department of Oncology, The 903rd Hospital of PLA, Hangzhou 310013, People's Republic of China
| | - Tao Wang
- Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
| | - Xiaoyuan Jia
- Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
| | - Tianxin Yang
- Department of Hematology, Zhejiang Province People's Hospital, Hangzhou 310014, People's Republic of China
| | - Xi Wang
- Department of Oncology, The 903rd Hospital of PLA, Hangzhou 310013, People's Republic of China
| | - Caiyun Fu
- Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China
| |
Collapse
|
2
|
Oliveira E, Bacelar TS, Ciudad J, Ribeiro MCM, Garcia DRN, Sedek L, Maia SF, Aranha DB, Machado IC, Ikeda A, Baglioli BF, Lopez-Duarte N, Teixeira LAC, Szczepanski T, Silva MLM, Land MGP, Orfao A, Costa ES. Altered neutrophil immunophenotypes in childhood B‑cell precursor acute lymphoblastic leukemia. Oncotarget 2017; 7:24664-76. [PMID: 27028865 PMCID: PMC5029732 DOI: 10.18632/oncotarget.8369] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Accepted: 03/02/2016] [Indexed: 12/22/2022] Open
Abstract
An increasing number of evidences suggest a genetic predisposition in acute lymphoblastic leukemia (ALL) that might favor the occurrence of the driver genetic alterations. Such genetic background might also translate into phenotypic alterations of residual hematopoietic cells. Whether such phenotypic alterations are present in bone marrow (BM) cells from childhood B-cell precursor (BCP)-ALL remains to be investigated. Here we analyzed the immunophenotypic profile of BM and peripheral blood (PB) maturing/matured neutrophils from 118 children with BCP-ALL and their relationship with the features of the disease. Our results showed altered neutrophil phenotypes in most (77%) BCP-ALL cases. The most frequently altered marker was CD10 (53%), followed by CD33 (34%), CD13 (15%), CD15/CD65 (10%) and CD123 (7%). Of note, patients with altered neutrophil phenotypes had younger age (p = 0.03) and lower percentages of BM maturing neutrophils (p = 0.004) together with greater BM lymphocyte (p = 0.04), and mature B-cell (p = 0.03) counts. No significant association was found between an altered neutrophil phenotype and other disease features. These findings point out the potential existence of an altered residual hematopoiesis in most childhood BCP-ALL cases.
Collapse
Affiliation(s)
- Elen Oliveira
- Clinical Medicine Postgraduate Program, College of Medicine, Rio de Janeiro Federal University (UFRJ), Rio de Janeiro, Brazil.,Cytometry Service, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG), UFRJ, Rio de Janeiro, Brazil
| | - Thiago S Bacelar
- Cytometry Service, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG), UFRJ, Rio de Janeiro, Brazil
| | - Juana Ciudad
- Departament of Medicine and Cytometry Service, Cancer Research Center (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca (USAL), Salamanca, Spain
| | | | - Daniela R N Garcia
- Clinical Medicine Postgraduate Program, College of Medicine, Rio de Janeiro Federal University (UFRJ), Rio de Janeiro, Brazil.,Cytogenetics Department, Bone Marrow Transplantation Unit and Oncology Post Graduation Program, National Cancer Institute (INCa), Rio de Janeiro, Brazil
| | - Lukasz Sedek
- Department of Pediatric Hematology/Oncology, Medical University of Silesia, Zabrze, Poland
| | - Simone F Maia
- Service of Pediatric Hematology, Federal Lagoa Hospital (HFL), Rio de Janeiro, Brazil
| | - Daniel B Aranha
- Clinical Medicine Postgraduate Program, College of Medicine, Rio de Janeiro Federal University (UFRJ), Rio de Janeiro, Brazil
| | - Indyara C Machado
- Service of Pediatric Hematology, São José do Avaí Hospital (HSJA), Itaperuna, Rio de Janeiro, Brazil
| | - Arissa Ikeda
- Service of Pediatric Hematology/Oncology, Servidores do Estado Federal Hospital (HSE), Rio de Janeiro, Brazil
| | - Bianca F Baglioli
- Service of Pediatric Hematology, Children's Cancer Hospital of Barretos, Barretos, São Paulo, Brazil
| | - Nathalia Lopez-Duarte
- Cytometry Service, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG), UFRJ, Rio de Janeiro, Brazil
| | - Lisandra A C Teixeira
- Clinical Medicine Postgraduate Program, College of Medicine, Rio de Janeiro Federal University (UFRJ), Rio de Janeiro, Brazil.,Cytometry Service, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG), UFRJ, Rio de Janeiro, Brazil
| | - Tomasz Szczepanski
- Department of Pediatric Hematology/Oncology, Medical University of Silesia, Zabrze, Poland
| | - Maria Luiza M Silva
- Cytogenetics Department, Bone Marrow Transplantation Unit and Oncology Post Graduation Program, National Cancer Institute (INCa), Rio de Janeiro, Brazil
| | - Marcelo G P Land
- Clinical Medicine Postgraduate Program, College of Medicine, Rio de Janeiro Federal University (UFRJ), Rio de Janeiro, Brazil.,Cytometry Service, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG), UFRJ, Rio de Janeiro, Brazil
| | - Alberto Orfao
- Departament of Medicine and Cytometry Service, Cancer Research Center (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca (USAL), Salamanca, Spain
| | - Elaine S Costa
- Clinical Medicine Postgraduate Program, College of Medicine, Rio de Janeiro Federal University (UFRJ), Rio de Janeiro, Brazil.,Cytometry Service, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG), UFRJ, Rio de Janeiro, Brazil
| |
Collapse
|
3
|
Manukyan G, Papajik T, Gajdos P, Mikulkova Z, Urbanova R, Gabcova G, Kudelka M, Turcsányi P, Ryznerova P, Prochazka V, Kriegova E. Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects. Oncotarget 2017; 8:84889-84901. [PMID: 29156691 PMCID: PMC5689581 DOI: 10.18632/oncotarget.20031] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Accepted: 07/25/2017] [Indexed: 12/14/2022] Open
Abstract
A growing body of studies highlights involvement of neutrophils in cancer development and progression. Our aim was to assess the phenotypic and functional properties of circulating neutrophils from patients with chronic lymphocytic leukemia (CLL). The percentage of CD54+ and CD64+ neutrophils as well as CD54 expression on these cells were higher in CLL patients than in age-matched healthy controls. Neutrophils from CLL produced more reactive oxygen species (ROS) compared to controls in both resting and activated conditions. Lipopolysaccharide-induced production of IL-1β and TNF-a as well as reduced TLR2 expression in neutrophils from CLL than in neutrophils from controls suggesting their tolerant state. Finally, phenotypic alterations of neutrophils, particularly elevation of CD64 and CD54 markers, correlated with disease activity and treatment, and low percentage of neutrophils. Taken together, the alterations in percentage and functional characteristics of neutrophils reflect the clinical course of CLL. Our data provide first evidence that neutrophils in CLL are permanently primed and have functional defects.
Collapse
Affiliation(s)
- Gayane Manukyan
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.,Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology NAS RA, Yerevan, Armenia
| | - Tomas Papajik
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Petr Gajdos
- Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic
| | - Zuzana Mikulkova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
| | - Renata Urbanova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Gabriela Gabcova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
| | - Milos Kudelka
- Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic
| | - Peter Turcsányi
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Pavlina Ryznerova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Vit Prochazka
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Eva Kriegova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
| |
Collapse
|
4
|
Weinberg OK, Hasserjian RP, Li B, Pozdnyakova O. Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. J Clin Pathol 2016; 70:109-115. [PMID: 27387988 DOI: 10.1136/jclinpath-2016-203863] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 06/14/2016] [Accepted: 06/15/2016] [Indexed: 11/04/2022]
Abstract
AIMS In recent years, multiparameter flow cytometry has been increasingly recognised as an important tool in diagnosis of myelodysplastic syndrome and acute myeloid leukaemia (AML). Assessment of myeloid and monocytic 'immunophenotypic' dysplasia by flow cytometry in de novo AML has not been evaluated. METHODS 97 cases of de novo AML cases were identified and reviewed by three hematopathologists. 'Immunophenotypic' dysplasia was assessed on blasts, monocytes and granulocytes by mean fluorescence intensity. RESULTS Using the 2008 WHO classification criteria, there were 53 AML-not otherwise specified (NOS) (55%) and 28 AML with myelodysplasia-related changes (AML-MRC) (29%), while 16 cases were ambiguous as to AML-MRC status due to limited maturing cells for morphologic but adequate events number for immunophenotypic evaluation (AML-not evaluable, 16%). Compared with AML-NOS, granulocytic cells in AML-MRC had higher CD33 expression but lower CD45, CD11b and CD15. Monocytes in AML-MRC had lower expression of CD14, CD56 and CD45. Morphologic dysplasia was associated with significantly lower granulocytic forward scatter, side scatter and CD10 but higher CD33 expression. CONCLUSIONS Our results suggest that the workup of AML cases should include flow cytometric assessment of granulocytes and monocytes. This analysis can aid a morphologic impression of multilineage dysplasia in distinguishing AML-MRC from AML-NOS, especially in cases with limited maturing myeloid cells.
Collapse
Affiliation(s)
- Olga K Weinberg
- Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Robert P Hasserjian
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Betty Li
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Olga Pozdnyakova
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| |
Collapse
|
5
|
Matarraz S, Almeida J, Flores-Montero J, Lécrevisse Q, Guerri V, López A, Bárrena S, Van Der Velden VHJ, Te Marvelde JG, Van Dongen JJM, Orfao A. Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry. CYTOMETRY PART B-CLINICAL CYTOMETRY 2015; 92:218-227. [DOI: 10.1002/cyto.b.21219] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Revised: 10/14/2014] [Accepted: 12/18/2014] [Indexed: 12/22/2022]
Affiliation(s)
- Sergio Matarraz
- Servicio De Citometría (NUCLEUS) and Department of Medicine; Centro De Investigación Del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL; Salamanca Spain
| | - Julia Almeida
- Servicio De Citometría (NUCLEUS) and Department of Medicine; Centro De Investigación Del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL; Salamanca Spain
| | - Juan Flores-Montero
- Servicio De Citometría (NUCLEUS) and Department of Medicine; Centro De Investigación Del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL; Salamanca Spain
| | - Quentin Lécrevisse
- Servicio De Citometría (NUCLEUS) and Department of Medicine; Centro De Investigación Del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL; Salamanca Spain
| | - Valentina Guerri
- Servicio De Citometría (NUCLEUS) and Department of Medicine; Centro De Investigación Del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL; Salamanca Spain
| | - Antonio López
- Servicio De Citometría (NUCLEUS) and Department of Medicine; Centro De Investigación Del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL; Salamanca Spain
| | - Susana Bárrena
- Servicio De Citometría (NUCLEUS) and Department of Medicine; Centro De Investigación Del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL; Salamanca Spain
| | | | - Jeroen G. Te Marvelde
- Department of Immunology; Erasmus MC, University Medical Center Rotterdam; Rotterdam The Netherlands
| | - Jacques J. M. Van Dongen
- Department of Immunology; Erasmus MC, University Medical Center Rotterdam; Rotterdam The Netherlands
| | - Alberto Orfao
- Servicio De Citometría (NUCLEUS) and Department of Medicine; Centro De Investigación Del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL; Salamanca Spain
| |
Collapse
|
6
|
Almeida M, Garc�a-Montero AC, Orfao A. Cell Purification: A New Challenge for Biobanks. Pathobiology 2015; 81:261-275. [DOI: 10.1159/000358306] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
7
|
Paíno T, Paiva B, Sayagués JM, Mota I, Carvalheiro T, Corchete LA, Aires-Mejía I, Pérez JJ, Sanchez ML, Barcena P, Ocio EM, San-Segundo L, Sarasquete ME, García-Sanz R, Vidriales MB, Oriol A, Hernández MT, Echeveste MA, Paiva A, Blade J, Lahuerta JJ, Orfao A, Mateos MV, Gutiérrez NC, San-Miguel JF. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia 2014; 29:1186-94. [DOI: 10.1038/leu.2014.321] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2014] [Revised: 10/31/2014] [Accepted: 11/04/2014] [Indexed: 01/06/2023]
|
8
|
Rodríguez-Caballero A, Henriques A, Criado I, Langerak AW, Matarraz S, López A, Balanzategui A, González M, Nieto WG, Cortesão E, Paiva A, Almeida J, Orfao A. Subjects with chronic lymphocytic leukaemia-like B-cell clones with stereotyped B-cell receptors frequently show MDS-associated phenotypes on myeloid cells. Br J Haematol 2014; 168:258-67. [PMID: 25252186 DOI: 10.1111/bjh.13127] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2014] [Accepted: 08/06/2014] [Indexed: 01/29/2023]
Abstract
An increasing body of evidence suggests the potential occurrence of antigen encounter by the cell of origin in chronic lymphocytic leukaemia (CLL) and CLL-like monoclonal B-cell lymphocytosis (MBL). However, the scenario in which this event might occur remains unknown. In order to gain insight into this scenario we investigated the molecular, cytogenetic and haematological features of 223 CLL-like (n = 84) and CLL (n = 139) clones with stereotyped (n = 32) versus non-stereotyped (n = 191) immunoglobulin heavy chain variable region (IGHV) amino acid sequences. Overall, stereotyped CLL-like MBL and CLL clones showed a unique IGHV profile, associated with higher IGHV1 and lower IGHV3 gene family usage (P = 0·03), longer IGHV complementary determining region 3 (HCDR3) sequences (P = 0·007) and unmutated IGHV (P < 0·001) versus non-stereotyped clones. Whilst the overall size of the stereotyped B-cell clones in peripheral blood did not appear to be associated with the CLL-related cytogenetic profile of B-cells (P > 0·05), it did show a significant association with the presence of myelodysplastic syndrome (MDS)-associated immunophenotypes on peripheral blood neutrophils and/or monocytes (P = 0·01). Altogether our results point to the potential involvement of different selection forces in the expansion of stereotyped vs. non-stereotyped CLL and CLL-like MBL clones, the former being potentially favoured by an underlying altered haematopoiesis.
Collapse
Affiliation(s)
- Arancha Rodríguez-Caballero
- Department of Medicine and Cytometry Service, Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca (USAL), Salamanca, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Matarraz S, Paiva B, Díez-Campelo M, Bárrena S, Jara-Acevedo M, Gutiérrez ML, Sayagués JM, Sánchez ML, Bárcena P, Garrastazul MP, Berruezo MJ, Duran JM, Cerveró C, García-Erce JA, Florensa L, Méndez GD, Gutierrez O, Del Cañizo MC, van Dongen JJM, San Miguel JF, Orfao A. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations. Leukemia 2014; 28:1747-50. [PMID: 24625552 DOI: 10.1038/leu.2014.103] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- S Matarraz
- Department of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain
| | - B Paiva
- Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
| | - M Díez-Campelo
- Department of Hematology, University Hospital, IBSAL and University of Salamanca, Salamanca, Spain
| | - S Bárrena
- Department of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain
| | - M Jara-Acevedo
- Department of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain
| | - M L Gutiérrez
- Department of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain
| | - J M Sayagués
- Department of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain
| | - M-L Sánchez
- Department of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain
| | - P Bárcena
- Department of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain
| | - M P Garrastazul
- Department of Hematology, Hospital Punta Europa, Algeciras, Spain
| | - M J Berruezo
- Department of Hematology, Hospital Punta Europa, Algeciras, Spain
| | - J M Duran
- Department of Hematology, Hospital La Línea, Cádiz, Spain
| | - C Cerveró
- Department of Hematology, Hospital Virgen de la Luz, Cuenca, Spain
| | | | - L Florensa
- Department of Hematology, Hospital del Mar, Barcelona, Spain
| | - G D Méndez
- Department of Hematology, Hospital de Jerez, Cádiz, Spain
| | - O Gutierrez
- Department of Hematology, Rio Hortega Hospital, Valladolid, Spain
| | - M C Del Cañizo
- Department of Hematology, University Hospital, IBSAL and University of Salamanca, Salamanca, Spain
| | - J J M van Dongen
- Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - J F San Miguel
- Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
| | - A Orfao
- Department of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain
| |
Collapse
|
10
|
Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia 2013; 28:1-14. [DOI: 10.1038/leu.2013.242] [Citation(s) in RCA: 87] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Revised: 08/06/2013] [Accepted: 08/09/2013] [Indexed: 01/02/2023]
|
11
|
Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJ, Orfao A. Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol 2013; 31:415-25. [DOI: 10.1016/j.tibtech.2013.04.008] [Citation(s) in RCA: 80] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Revised: 04/26/2013] [Accepted: 04/28/2013] [Indexed: 12/15/2022]
|